TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$230 Million

Pliant Therapeutics

Follow-on Offering

Bookrunner, July 2022

Pliant Therapeutics, Inc. (PLRX) (“Pliant”) is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Pliant's lead product candidate, PLN-74809, is an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis Institutes for Biomedical Research, Inc., or Novartis. In addition to clinical stage programs, Pliant currently has preclinical integrin-based programs targeting oncology and muscular dystrophies.